CRISPR Therapeutics Stock News

Cathie Wood and her funds are generating a lot of interest among investors for smart picks, and these Cathie Wood stocks are worth a look. The post 7 Cathie Wood Stock Favorites to Keep on Your Radar

As the saying goes, bulls and bears make money. And today in these three Cathie Wood stocks both camps should be ready for action The post 3 Cathie Wood Stocks To Trade for Bulls as Well as Bears appe

A crowded field could take years to thin out.

CRISPR Therapeutics' clinical programs are progressing nicely, showing excellent safety and efficacy, validating the prospects of its novel technology as a disruptive force in the biotech industry. Di

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year bef

Looking for a terrific value in the biotechnology space? It doesn't get much better than CRSP stock, which just entered a buy zone.

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

The stock dropped roughly $40 per share over the course of the month.

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are

Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.

Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate. The post CRSP Stock: The Good News Goosing CRISPR Therapeu

CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 125.30% and 32.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

- More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-